


Retrorsine

Cat. No.:	HY-N6638
CAS No.:	480-54-6
Molecular Formula:	C ₁₈ H ₂₅ NO ₆
Molecular Weight:	351.39
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes ^{[1][2]} .
In Vitro	Retrorsine (60-240 μM; 24 hours) significantly reduces HSEC-CYP3A4 cells viability, depletes GSH, and increases formation of pyrrole-protein adducts ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[3]
	Cell Line: HSEC-CYP3A4 cells
	Concentration: 60 μM, 120 μM, 240 μM
	Incubation Time: 24 hours
	Result: Significantly decreased cell viability.
In Vivo	Retrorsine (30 mg/kg; i.p.; twice) impairs liver regeneration in the PBL model not only by an S or G2/M phase block, but also by a block located before the G1/S transition of the cell cycle ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
	Animal Model: Male Wistar rats (180±20 g), portal branch ligation (PBL) model ^[1]
	Dosage: 30 mg/kg
	Administration: Intraperitoneal injection, twice, separated by 2-week interval
	Result: Strongly impaired the liver weight gain, protein and DNA synthesis as well as induction of cell cycle related proteins in the regenerating lobes after PBL.

REFERENCES

[1]. F J Cubero, et al. Hepatic proliferation in Gunn rats transplanted with hepatocytes: effect of retrorsine and tri-iodothyronine. Cell Prolif. 2005 Jun;38(3):137-46.

[2]. F J Cubero, et al. Hepatic proliferation in Gunn rats transplanted with hepatocytes: effect of retrorsine and tri-iodothyronine. Cell Prolif. 2005 Jun;38(3):137-46.

[3]. Yao Lu, et al. Establishment of a novel CYP3A4-transduced human hepatic sinusoidal endothelial cell model and its application in screening hepatotoxicity of pyrrolizidine alkaloids. J Environ Sci Health C Toxicol Carcinog. 2020;38(2):169-185.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA